CA 19-9 in non-neoplastic liver diseases. A clinical and laboratory study
- 15 September 1992
- journal article
- research article
- Published by Elsevier in Clinica Chimica Acta; International Journal of Clinical Chemistry
- Vol. 210 (1-2) , 145-151
- https://doi.org/10.1016/0009-8981(92)90053-s
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Serum CA 19-9 and alpha-fetoprotein levels in primary hepatocellular carcinoma and liver cirrhosisCancer, 1991
- CA 19-9 and CA 50 in Benign and malignant pancreatic and biliary diseasesCancer, 1988
- Tumor markers carcinoembryonic antigen, tissue polypeptide antigen, and carbohydrate antigen 19/9 in liver diseasesJournal of Surgical Oncology, 1988
- Carbohydrate antigen 19-9 as a serum marker of hepatocellular carcinoma: Comparison with alpha-foetoproteinBritish Journal of Cancer, 1987
- Role of hepatic dysfunction and bilirubin on CA 19-9 levels in cirrhotic patientsGastroenterology, 1987
- New carbohydrate tumor markersGastroenterology, 1986
- Prospective Evaluation of the Diagnostic Efficacy of CA 19–9 Assay as a Marker for Gastrointestinal CancersDigestion, 1986
- Determination and significance of a new carbohydrate antigen CA19-9 in digestive system cancers.Japanese Journal of Medicine, 1985